Bristol-Myers Squibb to Sell Erbitux in Canada
Posted on: Friday, 2 May 2008, 12:01 CDT
Bristol-Myers Squibb has decided to sell Erbitux, the drug which treats colorectal, head and neck cancer, in Canada after a two-year price squabble with the Patented Medicine Prices Review Board, reported CBC News.
Erbitux was approved by Health Canada in September 2005. But owing to disagreement over the drug price with the Patented Medicine Prices Review Board (PMPRB), a quasi-judicial body that protects consumers by ensuring that the manufacturers' prices of patented medicines are not excessive, Bristol-Myers Squibb refused to launch Erbitux in Canada.
According to Marc Osborne, director of public affairs and government relations for Bristol-Myers Squibb, the drug's impact on patient survivability and the importance of the drug to Canadian drug market has motivated the company to settle for the drug price set by the PMPRB.
Erbitux is mainly used to treat colorectal cancer that has metastasized when other drugs have failed.
Source: Datamonitor
Related Articles
- Generics Will Benefit As 75 Drugs Lose Their Patent Protections
- FDA Approves New Cancer Drug Erbitux
- Factors Are Examined on What Companies Need to Consider When Determining a Drug's Market Price in the Us
- Canadian Pharmaceutical Manufacturers Begin to Raise Patented Drug Prices
- Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva(R) (Efavirenz) and Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate)
- Drug Plans' Prices Unveiled
- Impotence Drugs Viagra, Cialis, Levitra Could Cause Blindness: Health Canada
- Merrion Pharmaceuticals, Inc. Is Issued a United States Drug Delivery System Patent
- Heart Drug Pill Priced at $1.80
- Some People Give Up Drugs As Prices Jump
 |
 |
User Comments (0)
RSS Feeds